30 completed, 7 unknown, 5 terminated, 2 withdrawn. 46 Phase 2, 13 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 46 | Completed 30, Unknown 7, Terminated 5, Withdrawn 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 13 | Completed 8, Terminated 3, Unknown 2 |
Follow Angioimmunoblastic T-cell Lymphoma: new trials by email Literature Review of Angioimmunoblastic T-cell Lymphoma trials Research Report on Angioimmunoblastic T-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tazemetostat Plus CHOP in 1L T-cell Lymphoma Tazemetostat, Doxorubicin, Vincristine - Lymphoma, Peripheral T Cell Lymphoma | Phase 2 | Withdrawn | Eric Jacobsen, MD | 2024-12-24 | 2026-04-01 | |
| Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine - Angioimmunoblastic T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huijing Wu | 30 | 2023-12-12 | 2024-01-25 |
| Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma Azacitidine, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Peking Union Medical College Hospital | 20 | 2022-01-01 | 2022-01-05 |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma Cyclophosphamide, Doxorubicin, Vincristine - Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 170 | 2021-10-08 | 2026-10-02 |
| Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL Sintilimab, Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Sun Yat-sen University | 83 | 2021-04-15 | 2021-04-05 |
| Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma Chidamide, Cyclophosphamide, Doxorubicin - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 23 | 2018-12-29 | 2022-04-20 |
| Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma AUTO4 - T Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified | Phase 1 / Phase 2 | Terminated | Autolus Limited | 20 | 2018-08-30 | 2026-03-16 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms Tislelizumab - Peripheral T Cell Lymphoma, PTCL | Phase 2 | Completed | BeiGene | 77 | 2018-04-13 | 2024-10-26 |
| Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Brentuximab Vedotin, Cyclophosphamide, Doxorubicin - Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative | Phase 2 | Active not recruiting | City of Hope Medical Center | 48 | 2017-05-25 | 2026-08-21 |
| Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) Chidamide - Angioimmunoblastic T-cell Lymphoma | Phase 2 | Unknown | Qingdao University | 30 | 2017-03-01 | 2017-09-25 |
| A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Brentuximab vedotin - T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Completed | Deepa Jagadeesh | 23 | 2016-06-17 | 2025-11-21 |
| CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma anti-CD7 CAR-pNK cells - Acute Myeloid Leukemia, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 / Phase 2 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 10 | 2016-03-01 | 2016-12-06 |
| Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma romidepsin, lenalidomide, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Northwestern University | 30 | 2015-06-11 | 2026-06-12 |
| Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Enasidenib - Solid Tumor, Glioma | Phase 1 / Phase 2 | Completed | Celgene | 21 | 2014-12-08 | 2021-02-23 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study Cyclophosphamide, Gemcitabine, Doxorubicin - Peripheral T-cell Lymphoma NOS, Anaplastic Large Cell Lymphoma, ALK-Negative | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 87 | 2012-03-01 | 2018-03-15 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
Showing 20 of 46. Sign in to see all of them.
Immunoblastic Lymphadenopathy (46) · Lymphoma, Large-Cell, Anaplastic (34) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (30) · Lymphoma, Extranodal NK-T-Cell (28) · Lymphoma, B-Cell, Marginal Zone (26) · Lymphoma, Follicular (26) · Lymphoma, Large B-Cell, Diffuse (26) · Lymphoma, T-Cell, Peripheral (26) · Leukemia, Lymphocytic, Chronic, B-Cell (25) · Lymphoma, Mantle-Cell (25) · Lymphoma, T-Cell, Cutaneous (25) · Mycosis Fungoides (25) · Sezary Syndrome (25) · Waldenstrom Macroglobulinemia (25) · Burkitt Lymphoma (22)
Hemic and Lymphatic Diseases (46) · Immune System Diseases (46) · Immunoproliferative Disorders (46) · Lymphadenopathy (46) · Lymphatic Diseases (46) · Lymphoproliferative Disorders (46) · Neoplasms (41) · Neoplasms by Histologic Type (41) · Lymphoma (37) · Hematologic Diseases (32) · Leukemia, Lymphoid (32) · Leukemia (31) · Lymphoma, T-Cell (28) · Lymphoma, B-Cell (27) · Disease Attributes (26)
Cyclophosphamide (10) · Whole-Body Irradiation (9) · fludarabine phosphate (9) · Mycophenolic Acid (8) · Peripheral Blood Stem Cell Transplantation (8) · Cyclosporine (6) · Etoposide (6) · Doxorubicin (5) · Prednisone (5) · Rituximab (5) · Vincristine (5) · Gene Expression Profiling (4) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (4) · Tacrolimus (4) · Azacitidine (3)
Fred Hutchinson Cancer Center (9) · National Cancer Institute (NCI) (8) · Mayo Clinic (3) · Northwestern University (2) · University of Washington (2) · Alliance for Clinical Trials in Oncology (1) · Autolus Limited (1) · BeiGene (1) · Case Comprehensive Cancer Center (1) · Celgene (1) · City of Hope Medical Center (1) · Deepa Jagadeesh (1) · Eric Jacobsen, MD (1) · Huijing Wu (1) · Massachusetts General Hospital (1)
United States (35) · China (7) · Italy (6) · Canada (3) · France (2) · United Kingdom (2) · Germany (1) · Malaysia (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1)
Brenda Sandmaier (3) · Ajay Gopal (2) · David Maloney (2) · Adam Petrich, MD (1) · Alex F Herrera (1) · Anas Younes (1) · Andre Goy (1) · Craig Reeder, M.D. (1) · Darryl Tan, MBBS MMED (1) · David Cunningham, MD FRCP (1) · Deepa Jagadeesh, MD, MPH (1) · Eric Jacobsen, MD (1) · George Chen (1) · Hillard Lazarus (1)
PMID 32499241, PMID 19900571, PMID 24241210, PMID 26077240, PMID 26213141, PMID 26688485, PMID 26764356, PMID 28054442, PMID 28314788, PMID 29703335, PMID 35170082, PMID 37276067, PMID 37327113, PMID 39067464, PMID 39528665
P30CA015704 (7), P01CA018029 (3), 2017 (2), P01CA078902 (2), 2014 (1), N01CM00039 (1), N01CM00070 (1), N01CM17003 (1), N01CM62202 (1), P30CA008748 (1), P30CA015083 (1), P30CA016058 (1), P30CA016672 (1), P30CA033572 (1), P30CA036727 (1)